

Dicot presents interim report Q1 2024

Press release: Uppsala, Sweden, May 6, 2024. Dicot AB (publ) publishes its interim report for the first quarter 2024. The report is available as an attached document and on the company's website www.dicot.se.

First quarter, January-March 2024

- Net sales amounts to KSEK 0 (0)
- Earnings after financial items amounts to KSEK -13,638 (-9,944)
- Earnings per share amounts to SEK -0.02 (-0.03)

”The safety profile demonstrated by LIB-01 in the Phase 1 study is very good, and to be honest, one can hardly get better results from a safety study. And thanks to exploratory measurements, we have managed to identify an efficacy signal, even though it was not the main purpose of the study. We see that the increased erectile function for some has been experienced 28 days after first dosing”, says Elin Trampe, CEO.

Significant events during the quarter

- Positive results from the first part of the phase 1 study are presented; showing a very good safety profile, no serious side effects, and a good exposure in the body
- Patent application is filed for a new manufacturing method of the starting material through cell culture
- The preclinical research results are presented at the European Society for Sexual Medicine

Significant events after the quarter

- Results from the final part of the phase 1 clinical trial show a very good safety profile and an efficacy signal is detected. Improved erectile function is reported through self-assessment forms and measurements, for some it persisted after 28 days at the end of the study
- Preparations for clinical phase 2a begin; study drug is manufactured and partner to conduct the study is procured

For further information, please contact:

Elin Trampe, CEO

Phone: +46 72 502 1010

E-mail: elin.trampe@dicot.se

Björn Petersson, CFO

Phone: +46 76 109 0000

E-mail: bjorn.petersson@dicot.se

DICOT

About Dicot AB

Dicot is developing the drug candidate LIB-01, which will be a potency agent to better treat erectile dysfunction and premature ejaculation. The ambition is to create a drug with significantly longer effect and far fewer side effects, compared to current available drugs. Today, over 500 million men suffer from these sexual dysfunctions and the market is valued at USD 8 billion. Dicot's strategy is to develop LIB-01 under own auspices until phase 2a studies and thereafter in partnership with larger, established pharmaceutical companies, finance and develop LIB-01 further to a registered pharmaceutical on the world market.

Dicot is listed on Spotlight Stock Market and has approximately 5,500 shareholders. For more information, please visit www.dicot.se.

This information is information that Dicot AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication through the contact person set out above, on May 6, 2024, at 07.50 CET.
